Cramer’s Analyst Says Eli Lilly’s GLP-1 Stock Rally Has Years Left to Run
Eli Lilly (LLY) posted a blowout quarter, and Mad Money says the GLP-1 drugmaker’s stock story is far from over.
Jim Cramer and CNBC analyst Jeff Marks called Eli Lilly and Nvidia top momentum stocks.
Why Eli Lilly’s GLP-1 Stock Still Has Room to Run
The comment came during a viewer question about how price targets get set. Cramer raised Eli Lilly and Nvidia’s runs specifically when asking about the process.
Marks, the CNBC Investing Club’s portfolio analyst, said stocks like these need a longer time horizon than most.
“Stocks like that you also have to look out years out in advance, too. Especially in the case of Eli Lilly, where it’s more of towards the end of the decade is where it’s GLP-1 sales.”
— Jeff Marks, CNBC Investing Club portfolio analyst, on Mad Money
Eli Lilly’s second-quarter results back that framing. Revenue hit $23 billion, up 48% year over year. A 60% jump in sales volume offset a 13% drop in realized prices.
Management raised full-year revenue guidance to a range of $85 billion to $87 billion. Mounjaro sales rose 91% to $9.9 billion worldwide. Zepbound’s U.S. revenue grew 44% to $4.9 billion.
Cramer’s other 2026 stock picks lean on similarly durable, multi-year themes rather than short-term trades.
Global GLP-1 Demand Is Still Early
Eli Lilly’s international business is growing even faster than its U.S. business. Revenue outside the U.S. jumped 80% to $8.6 billion in the quarter, while volume surged 113%.
That growth came even as prices outside the U.S. fell 36%. The decline followed Mounjaro’s addition to China’s National Reimbursement Drug List (NRDL), a program covering drug costs under public insurance.
Lower prices widen access for millions of new patients, even as they compress near-term margins. Morgan Stanley expects the global obesity and diabetes drug market to nearly double by 2035.
The firm projects $190 billion in sales, up from $79 billion in 2025. Oral GLP-1 pills and expanding insurance coverage are the main drivers behind that forecast.
For Marks and Cramer, runway and scale are why Eli Lilly’s momentum looks built for years, not quarters.